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Abstract
Rationale Members of the c-Jun N-terminal kinase (JNK)
family of mitogen-activated protein (MAP) kinases, and the
upstream kinase MKK7, have all been strongly linked with
synaptic plasticity and with the development of the neocortex.
However, the impact of disruption of this pathway on cogni-
tive function is unclear.
Objective In the current study, we test the hypothesis that
reduced MKK7 expression is sufficient to cause cognitive
impairment.
Methods Attentional function in mice haploinsufficient for
Map2k7 (Map2k7+/− mice) was investigated using the five-
choice serial reaction time task (5-CSRTT).
Results Once stable performance had been achieved,
Map2k7+/− mice showed a distinctive attentional deficit, in
the form of an increased number of missed responses, accom-
panied by a more pronounced decrement in performance over
time and elevated intra-individual reaction time variability.
When performance was reassessed after administration of
minocycline—a tetracycline antibiotic currently showing
promise for the improvement of attentional deficits in patients
with schizophrenia—signs of improvement in attentional per-
formance were detected.
Conclusions Overall,Map2k7 haploinsufficiency causes a dis-
tinctive pattern of cognitive impairment strongly suggestive of
an inability to sustain attention, in accordancewith those seen in
psychiatric patients carrying out similar tasks. This may be
important for understanding the mechanisms of cognitive dys-
function in clinical populations and highlights the possibility of
treating some of these deficits with minocycline.
Keywords Cognition . Attention .MKK7 . JNK .MAP
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Introduction
Considerable research efforts have focussed on the role of
mitogen-activated protein (MAP) kinase signalling cascades
in neuronal function. The importance of the MEK-ERK path-
way for cognition has become particularly clear (Samuels
et al. 2009), with the realisation that altered expression or
activity of pathway components leads to neurodevelopmental
disorders associated with intellectual disability (San Martin
and Pagani 2014). In contrast, less attention has been directed
at understanding the role of the c-Jun N-terminal kinase (JNK)
pathway in neuronal function. In this pathway, three genes
(MAPK8–10) encode isoforms of JNK (JNK1–3), which can
be activated by either of the upstream kinases MKK4 or
MKK7 (Wang et al. 2007; Coffey 2014). Mutations in JNK3
cause severe intellectual disability (Shoichet et al. 2006;
Kunde et al. 2013), whilst sequence variations in the
MAP2K7 gene (encodingMKK7) are associated with prefron-
tal cortex dysfunction and cognitive impairment in schizo-
phrenia (Winchester et al. 2012). This is consistent with ex-
perimental evidence that JNK1, MKK7 and MAP3K12 (a
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kinase upstream ofMKK7) are all crucial for the development
of the neocortex (Hirai et al. 2002; Hirai et al. 2011; Yamasaki
et al. 2011; Riches and Reynolds 2014; Xu et al. 2014), that
JNK1 (Li et al. 2007) and JNK2 (Chen et al. 2005) mediate
aspects of synaptic plasticity in the mature mouse hippocam-
pus and that MKK7 orthologue mutation impairs long-term
memory in Caenorhabditis elegans (Lakhina et al. 2015).
However, the impact of disruption of this pathway on specific
cognitive domains is unclear.
Many psychiatric disorders, including schizophrenia (Green
2006), are partially characterised by a distinctive pattern of
cognitive impairment that includes deficits in working memory
and in the ability to sustain attention. Several neurochemical
and metabolic changes observed in patients are centred on the
prefrontal cortex, a region involved in multiple cognitive pro-
cesses (Goldman-Rakic et al. 2000), including a crucial role in
aspects of normal attentional function (Rossi et al. 2009). This
raises the possibility that the decreased MKK7 expression, as
observed in patients with schizophrenia (Winchester et al.
2012), contributes directly to cognitive impairment.
Attentional function can be investigated in mice by the five-
choice serial reaction time task (5-CSRTT), a well-validated,
translational, operant paradigm that was based on the continuous
performance test (CPT) (Cornblatt et al. 1988; Nuechterlein
et al. 2008; Robbins 2002; Humby et al. 1999). The CPT reveals
attentional deficits in patients with neuropsychiatric disorders,
for example, patients with schizophrenia (Suwa et al. 2004),
bipolar disorder (Najt et al. 2005), including mania specifically
(Sax et al. 1999), and ADHD (Epstein et al. 2003). The 5-
CSRTTandCPT probe analogous behavioural and neuralmech-
anisms in the rodent and human brain (Robbins 2002), which
reinforces their relevance for the current NIMH Research
Domain Criteria (RDoC) initiative to focus on fundamental do-
mains of disease-relevant neural function (Casey et al. 2014).
Here, we test the hypothesis that reduced MKK7 expres-
sion is sufficient to cause cognitive impairment by investigat-
ing attentional function in mice haploinsufficient for Map2k7
(Map2k7+/− mice) by using the 5-CSRTT. We also test the
ability of minocycline to improve any deficits seen in the 5-
CSRTT, as minocycline is currently showing promise in clin-
ical trials as an adjuvant therapy for the treatment of cognitive
and negative symptoms of schizophrenia (reviewed in Chaves
et al. 2015). Specifically, available data suggest that
minocycline treatment improves attentional performance in
patients (Liu et al. 2014).
Materials and methods
Subjects
Mice heterozygous for a functional Map2k7 gene (Map2k7+/
−) were produced by replacement of a portion of exon 9 with a
PGK-Neo cassette as described in Sasaki et al. (2001) and
have been backcrossed onto the C57Bl6 mouse strain. For
the 5-CSRTT, 16 Map2k7+/− mice (7 female, 9 male) and 16
wild-type (WT) (7 female, 8 male) littermates were used,
18.9 ± 0.6 weeks of age at the start of the study, weighing
26.5 ± 0.7 g. All mice had experienced no previous procedures
(naïve to drugs and testing) and were singularly housed in a
temperature and humidity-controlled room (21 °C, 45–65 %
humidity) with a 12-h light/dark cycle (lights on at 08:00).
Mice were food restricted to 85–90 % of their free-feeding
weight and had ad libitum access to water throughout the
experiment. Testing was carried out daily between 09:00 and
17:00, Monday to Friday and in accordance with the Animals
(Scientific Procedures) Act 1986.
The five-choice serial reaction time task
In the 5-CSRTT, mice are required to respond via nose poke to
brief flashes of light that appear pseudorandomly in five avail-
able holes for a large number of trials (100) in order to receive
a liquid food reward from the magazine located in the wall
opposite a curved wall containing the holes. If an incorrect
response is made (poking a hole in which the stimulus did
not appear) or a missed trial occurs (not responding within
the limited hold (LH) period of 5 s), mice are punished by a
timeout period (5 s) along with illumination of the main
‘house light’. Trials are separated by an inter-trial interval
(ITI). Many aspects of their performance are automatically
recorded (see below for more information) in order to detect
differences in sustained, divided and spatial attention.
Apparatus
Eight mouse nine-hole operant chambers with dimensions of
12 by 13 cm (Campden Instruments Ltd., Cambridge
Cognition Limited) were used for the experiment, which were
enclosed in separate noise attenuation outer cabinets with a
ventilator fan providing low-level, constant background noise.
Mice were allocated an operant box randomly and were al-
ways tested in the same operant box throughout the experi-
ment. Nine circular holes are evenly spaced along a curved
side, of which four holes (holes 2, 4, 6 and 8) were blocked off
leaving five available for use in the task. The operant cham-
bers were controlled by Campden BNC Control software.
Performance measures
The performance measures for each session analysed were the
following:
& % Accuracy—calculated by the formula (number of cor-
rect responses / number of correct responses + number of
commission errors) × 100
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& % Omissions—calculated by the formula number of
missed trials / total number of trials completed
& Number of commission errors (nose poke during the LH
period into a hole where the stimulus had not been
presented)
& Number of premature responses (nose poke during the ITI
period)
& Number of perseverative responses (repeat nose poke fol-
lowing a correct response, in either the correct hole or
another hole, before collecting the food reward earned)
& Number of food magazine entries during the ITI
& Total number of trials completed
& Latency to make a correct response
& Mean reward collection latency
& Latency to consume reward (the duration the mouse was
in the food magazine for the first magazine entry follow-
ing reward delivery)
& Vigilance decrement (the extent to which performance de-
clined over the course of each session. Calculated by
subtracting the no. omissions data from final 20 trials
completed from the first 20 trials completed by each
mouse, for each session)
& Intra-individual variability of correct response times (IIV;
the variability of response times for each mouse over the
course of each session. Calculated by the standard devia-
tion of response times for each mouse per session)
& Intra-individual variability of incorrect response times
& Overall variability of correct response times—calculated
by the standard deviation of response times over the
course of five sessions
& Overall variability of incorrect response times
Habituation and training to high and stable performance
The protocol was according to our standard procedures
(Thomson et al. 2011). Mice were first habituated to the liquid
reinforcer (Yazoo® Strawberry Milkshake) and operant boxes
before undergoing 10 stages of training, which took 65 daily
sessions in total.
As stage 1–10 progress, the length of time for which the
stimulus is lit (stimulus duration 32–1 s) and LH (the length of
time the mice have to respond within, from the beginning of
the presentation of the stimulus 37–5 s) decrease and the
criteria become more stringent (>30 correct − >50 correct +
>80 % accuracy) until the mice are performing at a level
deemed appropriate to see differences in other aspects of per-
formance measures (e.g. % omissions) without being con-
founded by differences in task ability (Bari et al. 2008).
Once each individual mouse had reached criteria of the final
training stage 10, they were rested without daily training, whilst
mice not at criteria of stage 9 continued. Mice on rest were
given a reminder training session twice per week and if they
fell below criteria on a reminder session, they were trained daily
until criteria were reattained. This training regime is encouraged
for operant-based training (Oomen et al. 2013) because
‘over’training the mice that learn the task more quickly than
others could increase variability in performance and have con-
founding effects on the interpretation of the results.
Once all mice reached the final training stage, they moved
onto full test conditions which were the same as stage 10 apart
from the ITI which was not fixed at 5 s; instead, it
pseudorandomly varied between 2, 5, 10 or 15 s (vITI). This
prevents the use of a temporal strategy to complete the 5-
CSRTT (see Bari et al. 2008). As the overall ITI length was
increased, the maximum session duration was increased from
30 to 45 min. They were trained on the vITI until their perfor-
mance stabilised (which took 12 sessions), and the final 5-day
stable data were taken as ‘baseline’ performance.
Minocycline administration
Mice received minocycline in their normal drinking water
(0.5 mg/ml; protected from light; Sigma-Aldrich Co. M9511,
St. Louis, MA, USA) for a 7-day period. Fresh minocycline
solution was prepared every second day and provided at room
temperature. The dose and duration of the minocycline admin-
istration were chosen to reflect, as closely as possible, the treat-
ment protocols that are associated with symptomatic improve-
ment in patients with schizophrenia. Administration of
minocycline to mice in drinking water at 0.5 mg/ml, as used
here, produces a brain concentration of around 2 μM (Smith
et al. 2003), which is equivalent to the CSF concentrations
achieved in humans during standard antibacterial dosing re-
gimes (Macdonald et al. 1973; Agwuh and McGowan 2006).
This administration regime in mice is similar to that of McKim
et al. (2016). In the psychiatric context, improvement in patient
symptoms has been noted with 3 days of minocycline treatment
at equivalent doses (Miyaoka 2012). Mice were therefore tested
on the 5-CSRTT on days 4 and 7 after the start of minocycline
treatment. Consumption of minocycline-treated water wasmon-
itored daily for each mouse; they each received an average of
81.6 ± 3.1 mg/kg/day of minocycline.
Western blotting
Total protein from prefrontal cortex and hippocampal tissue
was extracted from male and female mice as follows:
Approximately 20 mg tissue was homogenised in RIPA buffer
(10 mMTris-HCL pH 7.4, 150 mMNaCl, 1 mMEDTA pH 8,
0.5 % w/v NP40, 0.1 % w/v SDS, 0.1 % w/v sodium
deoxycholate), protease inhibitor cocktail (Sigma, P8340)
and 1 M phosphatase inhibitor (Na3VO4). Cellular extracts
were then centrifuged at 10,000 RPM for 10 min at 4 °C
and supernatant collected. Protein concentrations of each in-
dividual sample were determined by using a Bradford protein
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assay and normalised. Protein was denatured by heating to
80 °C for 10 min in sample buffer (NuPAGE, Novex,
NP0007) and sample reducing agent (NuPAGE, Novex,
NP0004) before being subjected to SDS-PAGE in 10 % Bis-
Tris gel (NuPAGE, Novex, NP0302BOX) and transferred to
Invitrolon PVDF membrane (Novex, LC2005). Membranes
were placed in TTBS buffer (120 mM Tris-HCL pH 7.5,
150 mM NaCl, 0.05 % Tween-20) supplemented with 3 %
skimmed milk and blocked for 30 min at room temperature.
Membranes were then incubated with total MKK7 (tMKK7)
primary antibody (1:10,000, Genetex, #103563) overnight at
4 °C with constant agitation. The next day, they were washed
3 × 10 min in TTBS and then incubated with anti-rabbit sec-
ondary antibody (1:10,000) for 90 min at room temperature
with constant agitation. Blots were then washed once in
TTBS, then 2 × 10 min in TBS. Membrane-bound secondary
antibodies were detected by using Chemiluminescent HRP
Substrate (Immobilon, Millipore, WBKLS0100), and digital
images of Western blots were captured by PXi4 (Syngene).
Blots were then reprobedwithActin-HRP antibody (1:12,000,
Santa Cruz, sc-1616) overnight at 4 °C with constant agitation
and washed 3 × 10 min in TTBS. Actin specific bands were
detected by using ECL reagent (Signalfire, Cell Signalling
Technologies, 68835). Digital images of blots were quantified
by using ImageJ software, with tMKK7 values normalised to
Actin values.
Statistical analysis
All statistical analyses were carried out by using Minitab 16
Statistical Software. In all cases, results were considered sig-
nificant if p < 0.05. All data are presented as mean ± standard
error of the mean (SEM). Graphs were created by using
GraphPad Prism 3.03.
5-CSRTT data
One significantly atypical wild-type mouse was removed from
the study after initial training stage 10 because of consistent
abnormal repetitive behaviour (hyperactive rotational move-
ments) that prevented the mouse from completing the task
properly, disguising its true cognitive ability.
Comparison of the last 5-day stable performance between
two experimental groups is a method generally utilised to
examine group differences (Sanchez-Roige et al. 2012): The
last 5 days of well-trained, stable performance were analysed
between genotypes and, where appropriate, were compared
with performance on days 4 and 7 of the 7-day minocycline
treatment.
Unless stated otherwise, results were analysed by using a
two-way repeated measures ANOVA with daily session as a
within subject factor, genotype as a between subject factor and
each individual mouse nested within genotype. Minocycline
treatment data were analysed by a three-way repeated mea-
sures ANOVAwith session (i.e. day of minocycline treatment)
and treatment as within subject factors, genotype as a between
subject factor and each individual mouse nested within geno-
type. Before data from males and females were grouped, ef-
fects of gender were investigated and were non-significant for
all measurements excluding correct response latency.
Therefore, ‘gender’ was included in the statistical analysis as
a between subject factor for this measure. Post hoc tests were
conducted by using Tukey’s method for multiple comparisons
where appropriate. Anderson-Darling tests for normality were
carried out on all data, and if required, data were Box-Cox
transformed to the optimal λ; however, where means are re-
ported, untransformed data are used.
Western blot data
ImageJ data were analysed by a one-tailed or two-tailed t test
between genotypes.
Results
Map2k7+/− mice exhibit impaired attention
in the 5-CSRTT
Throughout training and once stable performance had been
attained,Map2k7+/− mice consistently showed a similar level
of accuracy as WT mice (Figs. 1a and 2a); in fact, they per-
formed marginally better at 94.6 ± 0.9 % accuracy compared
to WT littermates at 93.5 ± 0.7 % (F(1, 116) = 3.87; p = 0.052)
and made fewer commission errors overall (Map2k7+/−
4.063 ± 0.67; WT 5.33 ± 0.48) (F(1, 116) = 17.24;
p = 0.0001) (Fig. 1b). Even when challenged with shorter
stimulus durations,Map2k7+/−mice were still able to perform
to a similar extent to WT mice (Supplementary Fig. S1).
However, Map2k7+/− mice showed impaired attentional per-
formance, as indicated by an elevated number of omissions
made compared to wild-type littermates (F(1, 116) = 42.36;
p = 0.0001) (Fig. 1c). Moreover, this was consistent
Fig. 1 Map2k7+/− mice show an attentional deficit in the 5-CSRTT
which is not due to impairments in motivation and/or motor ability.
Map2k7+/− mice perform with similar accuracy (a) and make slightly
fewer commission errors (b) than WTs, miss more trials (c) and display
no inhibitory control deficit (d, e). Map2k7+/− mice display decreased
reward collection (f) and consumption (g) latencies, make more entries
into the reward magazine (h) and have similar correct response latencies
(i) compared to WTs. Each bar represents the average of the last 5-day
stable performance in the test stage. Data analysed by a two-way repeated
measures ANOVA (with daily session as a within subject factor, genotype
as a between subject factor and each individual mouse nested within
genotype) with Tukey’s post hoc and are presented as mean ± standard
error of the mean (SEM). **p < 0.01; ***p < 0.001, NWT = 15, NMap2k7+/
− = 16
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throughout training on the vITI (Fig. 2b). The significant ef-
fect of genotype on % omissions was also observed when
analysing the last 2 days of baseline performance rather than
the last 5. Inhibitory control measures showed thatMap2k7+/−
Psychopharmacology (2017) 234:293–305 297
mice were not impaired compared to WTs: They exhibited a
similar number of premature responses (Fig. 1d) and made
significantly fewer perseverative responses (F(1, 116) = 12.13;
p = 0.001) (Fig. 1e). However,Map2k7+/− mice were quicker
to collect (F(1, 116) = 240.97; p = 0.0001) and consume (F(1,
116) = 228.13; p = 0.0001) the reward (Fig. 1f, g), completed
almost all trials (99.6 ± 0.4 trials completed on average over
the 5-day baseline, compared to WTs completing all 100) and
had similar correct response latencies to WTs (F(1, 135) = 1.51;
p = 0.22) (Fig. 1i), showing good motivation to perform the
task.Map2k7+/−mice also entered the reward magazine more
frequently during the ITI period (i.e. when there is no reward
there to collect) than WTs (F(1, 116) = 51.92; p = 0.0001)
(Fig. 1h). There were also no significant differences between
WTs and Map2k7+/− mice for trials or sessions to criteria for
initial acquisition (just prior to vITI training) of the 5-CSRTT
(Supplementary Fig. S2). Collectively, these results indicate
thatMap2k7+/−mice exhibit an attentional deficit displayed as
increased omissions in the 5-CSRTT. Furthermore, this deficit
is not due to incapability of learning or carrying out of the
task, as shown by good accuracy and initial task acquisition.
The deficit is also not due to motivational/motoric impair-
ment: they displayed clear motivation to perform the task in
several aspects of performance, and they had slightly faster
reward collection and consumption latencies, which indicate
that measurements such as the number of omissions are not
confounded for reasons such as being physically incapable of
reaching the stimulus during the limited hold period.
Map2k7+/− omission deficit shows signs of being improved
by minocycline
Minocycline is a tetracycline antibiotic which is currently
showing promise in clinical trials for treatment of the negative
and cognitive symptoms of schizophrenia (reviewed in
Chaves et al. 2015). Overall, minocycline, administered for
7 days, improved the % omissions score for both Map2k7+/−
and WT mice by the seventh day of treatment (effect of ses-
sion F(3, 80) = 4.53; p = 0.006), by which time the significant
genotype difference at baseline had disappeared (Fig. 3a).
Furthermore, mice committed fewer omissions in the 5-
CSRTT by the seventh day of minocycline treatment than they
had ever achieved before the treatment (from 16.9 ± 1.7 at
baseline compared to 11.8 ± 2.9 by the seventh day of
minocycline treatment). Indeed, when performance over the
five baseline and two minocycline sessions was assessed, a
significant effect of session was detected (F(6, 182) = 2.57;
p = 0.02), without an overall significant effect of genotype
(F(1, 182) = 0.224; p = 0.224), and the two minocycline ses-
sions were both significantly different from each of the five
baseline sessions (Fisher’s post hoc test). Minocycline also
had the effect of removing the statistical significance of other
Fig. 2 Map2k7+/−mice consistently show a similar level of accuracy (a)
and a higher percentage of missed trials (b) thanWTmice over each vITI
training session of baseline performance (the last 5-day vITI training).
The significant effect of genotype on % omissions is also observed when
analysing the last 2 days of baseline performance rather than the last 5
(F(1, 29) = 8.71; p = 0.006). Numbers along the х-axis represent session
numbers from the first session of vITI training following basic training
stages 1–10. Data analysed by a two-way repeated measures ANOVA
(with daily session no. as a within subject factor, genotype as a between
subject factor and each individual mouse nested within genotype) with
Tukey’s post hoc and are presented as mean ± standard error of the mean
(SEM). **p < 0.01, ***p < 0.001 (genotype effect), NWT = 15, NMap2k7+/
− = 16
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phenotype-specific changes in performance, such as the num-
ber of commission errors and perseverative responses, the
latency to consume reward and the number of magazine en-
tries, but not for reward collection latency (Supplementary
Fig. S3).
Map2k7+/− mice display a deficit in ability to sustain
attention
For each daily session, the number of omissions performed by
eachmouse in the first 20 trials they completed was subtracted
from those performed during the final 20 trials to give a dif-
ference score that shows the extent to which performance for
eachmouse declines with session progress, which is known as
a ‘vigilance decrement’ (Parasuraman et al. 1987; Robbins
2002). On average, Map2k7+/− mice show a vigilance decre-
ment compared to WT mice (who did not) at baseline, mani-
festing as a significantly higher increase in the number of
omissions at the end of each session than the beginning, com-
pared to WT mice (F(1, 144) = 4.56; p = 0.034) (Fig. 3b).
Minocycline improved the number of omission difference
score by the seventh day of treatment overall, whilst, again,
removing the statistical significance between genotype groups
(Fig. 3b; effect of session: F(2, 182) = 4.66; p = 0.02).
Map2k7+/− mice are more varied in their response times
than WT mice
Intra-individual reaction time variability (IIV) is a measure of
variability in response times of a subject carrying out a task
over the course of a single session, thus quantifying short-term
fluctuations in an individual’s performance, and gives an in-
dication of the stability of cognitive processing (Kanai and
Rees 2011). IIV is perturbed in a number of neuropsychiatric
disorders including schizophrenia (Geurts et al. 2008; Kaiser
et al. 2008). We assessed IIV by measuring the variability of
reaction times of each mouse to make a correct and incorrect
response over the course of each daily session for every day of
baseline (stable) performance. Interestingly, Map2k7+/− mice
show significantly higher variability in their reaction times
when making incorrect responses (Fig. 4b; F(1, 125) = 4.58;
p = 0.034) but not when making correct responses (Fig. 4a;
F(1, 144) = 0.48; p = 0.491). This effect was maintained when
looking at group reaction time variability over the course of
the vITI training, including the 5-day stable performance
(Fig. 4c, e): Incorrect response times ofMap2k7+/−mice vary
significantly more on a day-to-day basis than WTs (Fig. 4e, f;
F(1, 4) = 6.43; p = 0.049), and group reaction time variability
for correct responses remained the same for all mice (Fig. 4c,
d; F(1, 4) = 1.13; p = 0.453). Minocycline did not have a
significant effect on the standard deviations of either correct
or incorrect response times of mice compared to baseline per-
formance (Fig. 4a, b).
Map2k7+/− mice have decreased tMKK7 in the prefrontal
cortex and hippocampus
Having established behavioural differences in Map2k7+/−
mice compared to their wild-type littermates, we investigated
Fig. 3 a Minocycline shows signs of improving the % omissions
deficit seen by Map2k7+/− mice. When the data from the 2 days
of minocycline are analysed along with the 5-day baseline, there is
a significant effect of session (F(6, 182) = 2.57; p = 0.02) and the
significant effect of genotype is no longer there (F(1, 182) = 0.224;
p = 0.224). Mice received 81.6 ± 3.1 mg/kg/day minocycline on
average. Data analysed by a three-way repeated measures ANOVA
with daily session and minocycline treatment as within subject fac-
tors, genotype as a between subject factor and each individual mouse
nested within genotype with Tukey’s post hoc and are presented as
mean ± standard error of the mean (SEM). ***p < 0.001 (vs. base-
line WT); ¥p < 0.05, ¥¥p < 0.01 (minocycline vs. baseline),
NWT = 15, NMap2k7+/− = 16. b Map2k7
+/− mice display a sustained
attentional deficit to a larger extent than WTs, reflected throughout
the last 5-day stable performance (baseline) by an increased propor-
tion of number of omissions occurring during the last 20 % of the
trials as compared to the first 20 % of each daily session.
Minocycline showed signs of improving the vigilance decrement in
mice by the seventh day of treatment. The difference score was
calculated by subtracting data collected during the first 20 trials com-
pleted from data collected during the final 20 trials completed by
each mouse, for each daily session. Data were then analysed by
either a two-way repeated measures ANOVA with daily session as
a within subject factor, genotype as a between subject factor, with
each individual mouse nested within genotype (data from Baseline),
or as a one-way ANOVA between genotypes (data from days 4 and
7 of treatment). Data are presented as mean ± standard error of the
mean (SEM). *p < 0.05 (vs. baseline WT); ¥p < 0.05 (minocycline
vs. baseline), NWT = 15, NMap2k7+/− = 16
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whether their heterozygosity is reflected in tMKK7 protein
levels in the brain. We were particularly interested in the pre-
frontal cortex and hippocampus because of their well-
established involvement in the cognitive deficits of schizo-
phrenia (Tregellas et al. 2014; Harrison 1999). The prefrontal
cortex (PFC) is required for attentional control in mice in
general (Kim et al. 2016) and for normal performance in the
5-CSRTT (Robbins 2002); hippocampal activity is correlated
with rat performance in the 5-CSRTT (Barbelivien et al.
2001), and hippocampal-prefrontal interactions have an essen-
tial role in cognition and behaviour in psychiatric disease
(reviewed in Sigurdsson and Duvarchi 2016). Whole protein
was extracted from prefrontal cortex and hippocampal tissue,
and Western blotting confirmed a significant reduction of
56 kDa MKK7 (ɣ isoform) in both brain regions (Fig. 5; pre-
frontal cortex F(1, 10) = 6.32, p = 0.031; hippocampus F(1,
17) = 5.52, p = 0.031).
Discussion
Mice haploinsufficient for the Map2k7 gene display an atten-
tional deficit in the 5-CSRTT that shows signs of being alle-
viated by minocycline, as well as an increased vigilance
decrement and intra-individual reaction time variability.
These deficits may reflect the decreased MKK7 protein levels
in the prefrontal cortex and hippocampus inMap2k7+/−mice.
Overall,Map2k7 haploinsufficiency causes behavioural alter-
ations in accordance with those seen in psychiatric patients
carrying out similar tasks, along with molecular changes rel-
evant to cognition and psychiatric disorders.
Map2k7+/− mice have decreased MAP2K7 protein
in the prefrontal cortex and hippocampus
Western blotting shows 56 kDa MKK7 (gamma isoform) to
be significantly decreased in the prefrontal cortex and hippo-
campus of Map2k7+/− mice compared to their wild-type lit-
termates. Decreased MKK7 in the PFC and hippocampus
(HC) is likely to have a disruptive effect on behaviour in the
5-CSRTT because hippocampal-prefrontal interactions occur
in various cognitive and behavioural functions, and disruption
of the PFC and HC is consistently implicated in psychiatric
disease (reviewed in Sigurdsson and Duvarci 2016). It is in-
teresting that a highly conserved SNP genetically associated
with schizophrenia is located immediately upstream of an al-
ternatively spliced exon only present in the MAP2K7ɣ iso-
form (Winchester et al. 2012). In the current study, although it
Fig. 4 Map2k7+/− mice have a
higher intra-individual reaction
time variability for incorrect, but
not correct, response times than
WTmice throughout baseline that
was not significantly alleviated by
minocycline treatment (a, b).
Increased variability also
occurred for Map2k7+/− mice
compared toWTs on average on a
day-to-day basis, seen during
training to a vITI and baseline
performance for latency to
incorrect (e) but not correct
responses (c). d, f The standard
deviations of each group over the
course of the last 5-day stable
performance (baseline). Data was
analysed by either a two-way
repeated measures ANOVAwith
daily session as a within subject
factor, genotype as a between
subject factor, with each
individual mouse nested within
genotype (data from a to e), or a
one-tailed t test between
genotypes (data from d andf).
Data are presented as mean ±
standard error of the mean (SEM).
*p < 0.05 (vs. WT), NWT = 15,
NMap2k7+/− = 16
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is possible that MAP2K7 may be decreased throughout the
whole brain, the reductions of MAP2K7ɣ in the PFC and HC
are likely to have functional implications which may explain
the deficits seen in the 5-CSRTT.
Map2k7+/− mice display an attentional deficit
Once stable performance had been attained, accuracy in the 5-
CSRTT was unimpaired in Map2k7+/−mice, indicating that
they are able to acquire the basic principles of the task to
normal levels of performance. Equally, there was no evidence
that these mice showed increased levels of impulsivity (pre-
mature responses) or compulsivity (perseveration), and re-
sponse latencies were slightly faster, indicating good motiva-
tion to perform the task. Strikingly, there was a very specific
deficit in that rates of missed responses were substantially
raised. The combination of results (increased omissions, good
accuracy, faster response latencies) suggests that Map2k7+/−
mice are unable to maintain the same levels of attention asWT
littermates, despite the fact that they appear to be highly mo-
tivated and understand how to carry out the task (Robbins
2002; Humby et al. 1999). Changes in accuracy levels as
opposed to omissions are frequently looked at as the main
measure of attentional function in the 5-CSRTT; however,
several studies confirm that increased omissions with the ab-
sence of an accuracy deficit probably result from stimulus
detection failures as a consequence of inattention, so long as
motoric/motivational impairments can be ruled out (Cordova
et al. 2006; Fletcher et al. 2007; Inglis et al. 2001; Risbrough
et al. 2002; Young et al. 2004, 2007; Tzanoulinou et al. 2015).
As well as omission deficits,Map2k7+/− mice also display
a slight vigilance decrement that manifests as an increased
amount of missed trials at the end of each session than at the
beginning, compared toWTmice, whose performance did not
decline over the course of a session. Patients with
schizophrenia consistently show a similar vigilance deficit
(Nestor et al. 1990, 1991; Hahn et al. 2012; Mass et al.
2000; Lysaker et al. 2010; Young et al. 2013), as do other
rodent models relevant to schizophrenia (Barnes et al. 2012,
2014).
Map2k7+/− mice also showed another form of attention
deficit: increased intra-individual reaction time variability
(IIV). IIV is a measure of variability in response times of a
subject carrying out a task over the course of a single session.
Originally seen merely as ‘noise’ in experimental data, re-
searchers now realise that it also reflects the stability of cog-
nitive processing and short-term fluctuations in performance
over a session (Kaiser et al. 2008) and it has been suggested
that IIV, as well as average task performance levels, are good
predictors for real-world functioning (Stuss et al. 2003). IIV is
consistently increased in schizophrenia (Kaiser et al. 2008),
ADHD (reviewed in Kuntsi and Klein 2012) and several other
psychiatric/cognitive disorders (Musso et al. 2015; Camicioli
et al. 2008; Geurts et al. 2008). Moreover, it is under investi-
gation as a reliable predictor for those who are at risk of de-
veloping schizophrenia (Shin et al. 2013), ADHD (Henrίquez-
Henrίquez et al. 2015) and even for cognitive function in itself
(Grand et al. 2016). Here, we looked at the distribution of
response times for each mouse over the course of each daily
session to give a measure of IIV. Map2k7+/− mice have in-
creased IIV for incorrect responses but not correct responses.
They also respond more variably on a day-to-day basis as a
group when making incorrect responses compared to WT
mice. IIV is an intriguing indicator of cognitive function be-
cause of its sensitivity, reliability and robustness across differ-
ent tasks that involve reaction times (Kuntsi and Klein 2011).
Establishing the underlying neural mechanisms to increased
IIV have been the focus of many studies which have shown
that increased IIV is correlated with disruption of dopamine
regulation in the PFC and subsequent increase of neural signal
Fig. 5 Western blot data show
mice heterozygous (HZ) for the
Map2k7 gene have significantly
decreased levels of MKK7
protein in the prefrontal cortex (a)
and hippocampus (b). WTwild
type, HZMap2k7+/− mice. Data
analysed for PFC and HC
separately by one-way ANOVA.
Data are presented as
mean ± standard error of the mean
(SEM). PFC *p < 0.05 (vs. WT),
NWT = 6, NMap2k7+/− = 6. HC
*p < 0.05 (vs. WT), NWT = 10,
NMap2k7+/− = 9
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to noise (MacDonald et al. 2006, 2009; Stefanis et al. 2005).
Nevertheless, other neural systems, hitherto unexplored, are
likely to be involved.
In addition toMap2k7+/−mice showing increased variabil-
ity in making incorrect responses, they also show altered la-
tencies in other measurements. They are quicker or similar in
all other latency measurements recorded:Map2k7+/−mice are
faster to collect and consume the reward and respond just as
quickly as WT mice when making a correct response. As well
as showing high motivation to complete the task, this set of
results suggests that when the Map2k7+/− mice have noticed
the stimulus, they are just as quick to respond correctly, but
when they miss a stimulus (probably due to inattention), they
have slower processing times than WTs before deciding to
take a guess. This may manifest as increased, and more vari-
able, incorrect response reaction times.
Map2k7+/− mice also make an increased number of maga-
zine entries during the ITI period compared toWTs. The ITI is
the period of time after they have collected the reward (if they
responded correctly) or after the timeout period (if they
responded incorrectly or missed the stimulus). Therefore,
Map2k7+/− mice are showing signs of anticipating wrongly
when they should receive a reward. Two possible explanations
for this are either because they are applying an increased
amount of salience to the reward or that they ‘like’ it more
thanWTmice. Previous studies in our lab have suggested that
Map2k7+/− mice do not experience increased preference for
sucrose (Thompson 2013); Map2k7+/− mice may therefore
apply more salience to the reward magazine than WTs.
Furthermore, Map2k7+/− mice appear to exhibit greater en-
trainment to the light stimulus as they do not show decreased
accuracy in conjunction with their increased % omissions
(Amitai and Markou 2010). Throughout any given trial, if
they fail to detect the stimulus, instead of guessing which hole
to poke (thus decreasing their % accuracy score), they with-
hold responding and consequently present with a missed trial.
The decreased numbers of commission errors made by
Map2k7+/−mice are also indicative of this. Frequent and mis-
taken trips to the reward magazine and strong entrainment to
the light stimuli may both be examples of Map2k7+/− mice
applying increased salience to some aspects of the task, which
is interesting in relation to psychiatric disorders that include
cognitive impairment, in particular schizophrenia, because
one of the symptoms in patients is applying too much salience
to particular, often irrelevant, aspects of the environment
(Kapur 2003).
Overall,Map2k7+/−mice display a specific attentional def-
icit which is unlikely to be explained by lack of motivation or
locomotor impairment. Although the molecular mechanisms
involved in decreased hippocampal MKK7 of Map2k7+/−
mice and how this results in impaired attention are currently
unclear, future molecular research will glean more informa-
tion about this.
Minocycline shows signs of improving some aspects
of performance in the 5-CSRTT
Minocycline is a semi-synthetic tetracycline antibiotic show-
ing promise in current clinical trials for the treatment of the
negative and cognitive symptoms of schizophrenia; impor-
tantly, it has shown ability to improve attentional deficits
(Liu et al. 2014). It is an ideal candidate for schizophrenia
treatment because it is already deemed safe for human con-
sumption and readily crosses the blood-brain barrier (Zink
et al. 2005). Minocycline was administered to Map2k7+/−
mice for 1 week in their drinking water, with testing on the
5-CSRTT on days 4 and 7 of the treatment. Minocycline im-
proved the % omissions score of the mice overall, but the
Map2k7+/− mice in particular showed signs of continual im-
provement of their % omissions score throughout minocycline
treatment, performing better on the seventh day of the treat-
ment than they had ever performed beforehand. Although
minocycline treatment did not have a significant effect on
the IIVof Map2k7+/− mice, in the same way as it affected %
omissions, the treatment improved performance of all mice
overall with respect to the vigilance decrement, including hav-
ing a particular influence on Map2k7+/− mice. Minocycline
also had this effect on other phenotype-specific changes in
performance, such as the number of commission errors and
perseverative responses, latency to consume reward and the
number of magazine entries. As minocycline has previously
been shown to improve attention deficits in human patients
with schizophrenia (Liu et al. 2014), these results further war-
rant the refinement of Map2k7+/− mice as a model of atten-
tional and possibly other cognitive impairments because the
ability to maintain and focus attention enhances performance
in other cognitive domains.
Minocycline has also been shown to improve reaction
times in healthy volunteers in a sustained attentional task
(Sofuoglu et al. 2011). Additionally, in a mouse model rele-
vant to schizophrenia produced by administration of an N-
methyl-D-aspartate receptor (NMDAR) antagonist, MK801,
minocycline improved deficits in prepulse inhibition and vi-
suospatial memory (Levkovitz et al. 2007) and also improved
phencyclidine-induced cognitive deficits in mice (Fujita et al.
2008). Despite minocycline having been shown to have ben-
eficial effects in both healthy and pathological (cognitive def-
icits) human and rodent studies, the exact mechanism of ac-
tion of minocycline is still unknown, although two main
mechanisms have been proposed with relation to cognition:
inhibition of activated microglia and/or enhancing glutamate
release via NMDARs (Liu et al. 2014; Lisiecka et al. 2015). It
is entirely conceivable that either or a combination of both of
these mechanisms are relevant in the current study because of
the potential for them both to interact with the MKK7/JNK
pathway. The JNK pathway is essential for pro-inflammatory
functions of microglia (Waetzig et al. 2005), and NMDARs
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are located upstream of the MKK7-JNK pathway (Centeno
et al. 2006), suggesting that altering microglia and/or
NMDAR activation states via minocycline has potential to
affect regulation of the MKK7/JNK pathway in order to pro-
duce a cognitive enhancing effect. More molecular and clini-
cal evidence onminocycline’s potential as an agent to improve
cognition is needed. However, our data support the concept
that this drug is effective in improving some aspects of atten-
tional function.
Conclusion
The results presented here demonstrate the importance of
MKK7-JNK signalling for attentional processes. MAP2K7 se-
quence variants show a strong genetic association with schizo-
phrenia (Winchester et al. 2012), and other kinases closely in-
volved in MKK7-JNK signalling have been detected as poten-
tially associatedwith schizophrenia in recent GWAS (Morris and
Pratt 2014; Schizophrenia Working Group of the Psychiatric
Genomics 2014). In summary, mice haploinsufficient for the
Map2k7 gene show deficits in attention, a core cognitive impair-
ment in many neuropsychiatric diseases (Millan et al. 2012), and
show signs of improvement in attentional performance with
minocycline treatment. Importantly, dissection of attentional pro-
cesses revealed impaired vigilance and impaired cognitive sta-
bility, particularly when attending to incorrect responses which
are highly relevant to ‘real-world’ functioning. Hence, the data
may be important for understanding the mechanisms of cogni-
tive dysfunction and highlight the possibility of treating some of
these deficits with minocycline.
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